Drugs / Efesovir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05060705 | Dec 2025 → Apr 2026 overdue | COVID-19 | Scientific Center for Anti-infectious Drugs, Kazakhstan | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Efesovir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05060705 ↗ |
| Route | Oral | “Efesovir oral solution in dose 0.125 ml / kg two times per day” NCT05060705 ↗ |